Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 10, 2025, titled "Press Release w.r.t Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, for OneSource flagship Unit 2 facility".
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma has informed the stock exchange about a press release dated April 10, 2025, announcing that its flagship Unit 2 manufacturing facility has received Good Manufacturing Practices (GMP) certification from ANVISA, Brazil's health regulatory agency. GMP certification is a mandatory quality standard required for pharmaceutical companies to manufacture and export products to Brazil. This marks an important regulatory milestone for the company, as ANVISA approval is recognized as one of the more stringent pharmaceutical quality certifications globally.
Positive for shareholders — this certification paves the way for Onesource to tap into the large Brazilian pharmaceutical market and strengthens its credibility for exports to other regulated markets, potentially boosting future revenue from international contracts.